Comprehensive Genomic Profiling and Therapeutic Implications for Taiwanese Patients with Treatment-naïve Breast Cancer

Overview

Journal Cancer Med

Specialty Oncology

Date 2024 Jun 19

PMID 38895905

Authors

Shang-Hung Chen

Ka-Po Tse

Yen-Jung Lu

Shu-Jen Chen

Yu-Feng Tian

Kien Thiam Tan

Chien-Feng Li

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer is a heterogeneous disease categorized based on molecular characteristics, including hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expression levels. The emergence of profiling technology has revealed multiple driver genomic alterations within each breast cancer subtype, serving as biomarkers to predict treatment outcomes. This study aimed to explore the genomic landscape of breast cancer in the Taiwanese population through comprehensive genomic profiling (CGP) and identify diagnostic and predictive biomarkers.

Methods: Targeted next-generation sequencing-based CGP was performed on 116 archived Taiwanese breast cancer specimens, assessing genomic alterations (GAs), including single nucleotide variants, copy number variants, fusion genes, tumor mutation burden (TMB), and microsatellite instability (MSI) status. Predictive variants for FDA-approved therapies were evaluated within each subtype.

Results: In the cohort, frequent mutations included PIK3CA (39.7%), TP53 (36.2%), KMT2C (9.5%), GATA3 (8.6%), and SF3B1 (6.9%). All subtypes had low TMB, with no MSI-H tumors. Among HR + HER2- patients, 42% (27/65) harbored activating PIK3CA mutations, implying potential sensitivity to PI3K inhibitors and resistance to endocrine therapies. HR + HER2- patients exhibited intrinsic hormonal resistance via FGFR1 gene gain/amplification (15%), exclusive of PI3K/AKT pathway alterations. Aberrations in the PI3K/AKT/mTOR and FGFR pathways were implicated in chemoresistance, with a 52.9% involvement in triple-negative breast cancer. In HER2+ tumors, 50% harbored GAs potentially conferring resistance to anti-HER2 therapies, including PIK3CA mutations (32%), MAP3K1 (2.9%), NF1 (2.9%), and copy number gain/amplification of FGFR1 (18%), FGFR3 (2.9%), EGFR (2.9%), and AKT2 (2.9%).

Conclusion: This study presents CGP findings for treatment-naïve Taiwanese breast cancer, emphasizing its value in routine breast cancer management, disease classification, and treatment selection.

Citing Articles

Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer.

Chen S, Tse K, Lu Y, Chen S, Tian Y, Tan K Cancer Med. 2024; 13(12):e7384.

PMID: 38895905 PMC: 11187859. DOI: 10.1002/cam4.7384.

References

Stephens P, Tarpey P, Davies H, Van Loo P, Greenman C, Wedge D . The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486(7403):400-4. PMC: 3428862. DOI: 10.1038/nature11017. View

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K . Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020; 21(10):1353-1365. DOI: 10.1016/S1470-2045(20)30445-9. View

Oh D, Bang Y . HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2019; 17(1):33-48. DOI: 10.1038/s41571-019-0268-3. View

Haleckova A, Benek O, Zemanova L, Dolezal R, Musilek K . Small-molecule inhibitors of cyclophilin D as potential therapeutics in mitochondria-related diseases. Med Res Rev. 2022; 42(5):1822-1855. DOI: 10.1002/med.21892. View

Ngoi N, Tan D . The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?. ESMO Open. 2021; 6(3):100144. PMC: 8141874. DOI: 10.1016/j.esmoop.2021.100144. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Desmedt C, Voet T, Sotiriou C, Campbell P . Next-generation sequencing in breast cancer: first take home messages. Curr Opin Oncol. 2012; 24(6):597-604. PMC: 3713550. DOI: 10.1097/CCO.0b013e328359554e. View

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

10.

Russnes H, Navin N, Hicks J, Borresen-Dale A . Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest. 2011; 121(10):3810-8. PMC: 3195464. DOI: 10.1172/JCI57088. View

11.

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

12.

Viale G, Trapani D, Curigliano G . Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. Biomed Res Int. 2017; 2017:4719194. PMC: 5523547. DOI: 10.1155/2017/4719194. View

13.

Joo L, Zhang T, Koka H, Lee D, Shi J, Lee P . Comparison of somatic mutation landscapes in Chinese versus European breast cancer patients. HGG Adv. 2022; 3(1):100076. PMC: 8756551. DOI: 10.1016/j.xhgg.2021.100076. View

14.

Mekonnen N, Yang H, Shin Y . Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors. Front Oncol. 2022; 12:880643. PMC: 9247200. DOI: 10.3389/fonc.2022.880643. View

15.

Kim Y, Yoo K, Goodman M . Differences in incidence, mortality and survival of breast cancer by regions and countries in Asia and contributing factors. Asian Pac J Cancer Prev. 2015; 16(7):2857-70. DOI: 10.7314/apjcp.2015.16.7.2857. View

16.

Chen S, Tse K, Lu Y, Chen S, Tian Y, Tan K . Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer. Cancer Med. 2024; 13(12):e7384. PMC: 11187859. DOI: 10.1002/cam4.7384. View

17.

Coombes R, Badman P, Lozano-Kuehne J, Liu X, Macpherson I, Zubairi I . Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nat Commun. 2022; 13(1):3246. PMC: 9187670. DOI: 10.1038/s41467-022-30666-0. View

18.

Bhoo-Pathy N, Yip C, Hartman M, Uiterwaal C, Devi B, Peeters P . Breast cancer research in Asia: adopt or adapt Western knowledge?. Eur J Cancer. 2012; 49(3):703-9. DOI: 10.1016/j.ejca.2012.09.014. View

19.

Zehir A, Benayed R, Shah R, Syed A, Middha S, Kim H . Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017; 23(6):703-713. PMC: 5461196. DOI: 10.1038/nm.4333. View

20.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X . Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016; 534(7605):47-54. PMC: 4910866. DOI: 10.1038/nature17676. View